2022-07-01
On July 4th 2022, Blue Ocean Capital Group ("BOCG") is honored to announce that four well-achieved experts with industry, academic and clinical background respectively, have joined its Scientific and Industrial Advisory Board ("The Advisory Board") to strengthen its investment and operational capabilities. They are Dr. Yan Shao, Dr. Yongqin Zeng, Prof. Jixi Li and Prof. Yanling Wen. The Advisory Board supports BOCG with opinions, suggestions and strategies in innovation and healthcare investment, and further empowers its portfolio companies.
Dr. Yan Shao has accumulated more than 30 years of experience in corporate management, investment and pharmaceutical commercialization. Dr. Shao served as CEO of Grand Pharmaceutical Group Limited (0512.HK) for more than 10 years. Under his leadership, the company accomplished a number of billion dollar cross-border M&As and grew the company into a billion listco. Prior to that, he worked for more than 15 years in investment banking and asset management with senior management positions. Dr. Shao earned an MBA degree from Peking university and a Ph.D. in Political Sciences and Administration from Beijing Normal University. Dr. Shao will advise BOCG's M&A opportunities in the healthcare sector, and provide commercialization and operation strategy to portfolio companies.
Dr. Yongqin Zeng worked at Philips for more than 20 years, during which she spent 10 years focusing on HealthTech, and she became an innovation senior director since 2006. She worked as a scientist, a leader on HealthTech innovation and on incubation, in the field of medical image equipment, Healthcare big data & medical AI, and chronic disease etc. Over the past four years, Dr. Zeng led Philips Venture China to explore and shape Phillips' external ecosystem with over 20 selected leading HealthTech startups. She is currently serving as a senior role in a technology college and sharing her experiences with future technology specialist. Dr. Zeng received her Ph.D. in Electronics engineering from Imperial College London, and joined an executive innovation education program from MIT Sloan and a joint senior executive program provided by CEIBS, Tsinghua University and Harvard University. Dr. Zeng will provide BOCG with guidance on the research and investment in medical devices, HealthTech and other innovative areas, and will assist and empower the industrial innovation and portfolio companies' commercialization strategy.
Prof. Jixi Li is a professor at the School of Life Sciences, Fudan University, Chief Scientist of the National Key research and development program of the Ministry of Science and Technology and PI of the State Key Laboratory of Genetic Engineering, and the recipient of the Shanghai Distinguished Professor "Oriental Scholar". Prof. Li worked as a postdoctoral fellow at The California Institute of Technology, Weill Cornell Medical School, Harvard Medical School, and Boston Children's Hospital. He has published more than 70 SCI papers in Cell, Immunity and other international journals as the corresponding or first author and has 11 patents approved. Furthermore, he led more than ten scientific research projects. Prof. Li earned a Ph.D in genetics from Fudan University and a Master's degree in biophysics from Zhejiang University. Prof. Li will equip BOCG with the knowledge of development and innovation research of the biotech industry.
Prof. Yanling Wen has worked in clinical research, scientific research and education for nearly 30 years. Currently, she is a professor and Chief Physician of the Department of Ultrasound in Affiliated Hospital of Sun Yat-sen University. She excels at ultrasound diagnosis and interventional ultrasound diagnosis and treatment of abdomen, small organs and peripheral blood vessels. In particular, she has unique clinical experience and innovative thinking in the application of new technologies such as contrast-enhanced ultrasound and elastography, as well as the interventional diagnosis and treatment of liver and breast tumors. Prof. Wen holds a doctor's degree in Imaging and Nuclear Medicine from Sun Yat-sen University. Prof. Wen will advise BOCG's investment strategies and recommendations on imaging medicine and clinical needs.
Mr. Frank Yang, the founding partner and CEO of BOCG, said：“We are honored to have these distinguished experts with decades of experience and remarkable achievements to join our Advisory Board. I believe their industry experience and vision will enhance BOCG's overall capabilities and provide valuable operational and strategic support to our portfolio companies. Throughout the years, BOCG has formed a professional, diverse and international investment team. We look forward to in-depth cooperation and make meaningful contribution to the healthcare industry.”
